| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14528799P | 1999-07-23 | 1999-07-23 | |
| US60145287 | 1999-07-23 | ||
| PCT/US2000/019849WO2001007028A2 (en) | 1999-07-23 | 2000-07-21 | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
| Publication Number | Publication Date |
|---|---|
| AU6228000Atrue AU6228000A (en) | 2001-02-13 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU62280/00AAbandonedAU6228000A (en) | 1999-07-23 | 2000-07-21 | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
| Country | Link |
|---|---|
| AU (1) | AU6228000A (en) |
| WO (1) | WO2001007028A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007513880A (en) | 2003-11-25 | 2007-05-31 | ノボ ノルディスク アクティーゼルスカブ | New salicylanilide |
| LT1937244T (en) | 2005-09-30 | 2018-11-12 | Io Therapeutics, Llc | Treatment of cancer with specific rxr agonists |
| CN104114171A (en) | 2011-12-13 | 2014-10-22 | Io治疗公司 | Autoimmune disorder treatment using RXR agonists |
| EP3368080B8 (en) | 2015-10-31 | 2023-04-26 | IO Therapeutics, Inc. | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones |
| WO2017091762A1 (en) | 2015-11-25 | 2017-06-01 | Io Therapeutics, Inc. | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer |
| DK3426303T3 (en) | 2016-03-10 | 2022-09-19 | Io Therapeutics Inc | TREATMENT OF MUSCLE DISORDERS WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES |
| CN109310769B (en) | 2016-03-10 | 2022-07-05 | Io治疗公司 | Treatment of autoimmune diseases with a combination of RXR agonists and thyroid hormones |
| KR20190017950A (en) | 2016-06-10 | 2019-02-20 | 아이오 테라퓨틱스, 인크. | Receptor selective retinoids and lexinidol compounds and immunomodulators for cancer immunotherapy |
| WO2019014352A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| JP2020526539A (en) | 2017-07-13 | 2020-08-31 | アイオー セラピューティクス インコーポレイテッド | Retinoid and lexinoid compounds showing selectivity for receptor subtypes and functions in combination with immunomodulators for cancer immunotherapy |
| CN111148514A (en) | 2017-08-31 | 2020-05-12 | Io治疗公司 | RAR selective agonists for cancer immunotherapy in combination with immunomodulators |
| CA3076373A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | Treatment of disease with esters of selective rxr agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| WO2023108012A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958954A (en)* | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5688957A (en)* | 1995-12-29 | 1997-11-18 | Allergan | (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity |
| US5808124A (en)* | 1996-06-21 | 1998-09-15 | Allergan | O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| US5763635A (en)* | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
| US5773594A (en)* | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| US5739338A (en)* | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
| US5728846A (en)* | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
| US5919970A (en)* | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| Publication number | Publication date |
|---|---|
| WO2001007028A2 (en) | 2001-02-01 |
| WO2001007028A3 (en) | 2001-08-30 |
| Publication | Publication Date | Title |
|---|---|---|
| AU1293101A (en) | Ep4 receptor selective agonists in the treatment of osteoporosis | |
| AU2666901A (en) | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | |
| HRP20060251B1 (en) | Substituted oxasolidinones and their use | |
| ZA200108413B (en) | Use of glycosyceramide synthesis inhibitors in therapy. | |
| IL147655A0 (en) | Applicator for use in reflexotherapy | |
| IL147656A0 (en) | An applicator for use in reflexotherapy | |
| AU6228000A (en) | The use of retinoid receptor antagonists in the treatment of prostate carcinoma | |
| AU4923200A (en) | Isothiazolecarboxamides and their use as microbicides | |
| AU3086900A (en) | Device for the complex treatment of disorders of the prostate | |
| HK1043059A1 (en) | Tumor necrosis factor antagonists and their use inendometriosis. | |
| IL145775A0 (en) | 13 transmembrane protein expressed in prostate cancer | |
| AU2962200A (en) | Use of agonists or antagonists of mip-3a in therapy | |
| AU2001248971A1 (en) | Use of npy y1 receptor agonists in the treatment of pain conditions | |
| HUP0202339A3 (en) | Use of cortisol antagonists in the treatment of heat failure | |
| AU2297201A (en) | Uses of antileukoprotease in carcinoma | |
| GB2356362A9 (en) | Ultrasonic nebuliser | |
| GB9810920D0 (en) | Therapeutic use | |
| GB9911238D0 (en) | Therapeutic use | |
| GB9900364D0 (en) | Multifilar double-star micometer | |
| GB9811624D0 (en) | Therapeutic use | |
| GB9923117D0 (en) | Insect-paper and methods for its formation and use | |
| AU2021700A (en) | Methods of using temozolomide in the treatment of cancers | |
| AU1342301A (en) | Improvements in water generating devices | |
| TW443645U (en) | Grounding line set structure for personal use | |
| GB9921953D0 (en) | Therapeutic use |
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |